ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

NASDAQ:AAPG

22.14 USD
-1.52 (-6.42%)
Last: Mar 3, 2026, 02:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

AAPG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. AAPG may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AAPG is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • AAPG had negative earnings in the past year.
  • AAPG had a negative operating cash flow in the past year.
  • AAPG had negative earnings in each of the past 5 years.
  • AAPG had a negative operating cash flow in each of the past 5 years.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500M -1B

1.2 Ratios

  • AAPG has a Return On Assets of -38.05%. This is comparable to the rest of the industry: AAPG outperforms 59.04% of its industry peers.
  • AAPG's Return On Equity of -174.06% is on the low side compared to the rest of the industry. AAPG is outperformed by 66.54% of its industry peers.
Industry RankSector Rank
ROA -38.05%
ROE -174.06%
ROIC N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • AAPG has a better Gross Margin (90.87%) than 92.50% of its industry peers.
  • AAPG's Gross Margin has improved in the last couple of years.
  • AAPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AAPG has more shares outstanding
  • The number of shares outstanding for AAPG has been increased compared to 5 years ago.
  • The debt/assets ratio for AAPG has been reduced compared to a year ago.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -0.14, we must say that AAPG is in the distress zone and has some risk of bankruptcy.
  • AAPG has a Altman-Z score (-0.14) which is comparable to the rest of the industry.
  • AAPG has a Debt/Equity ratio of 1.99. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.99, AAPG is doing worse than 78.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.99
Debt/FCF N/A
Altman-Z -0.14
ROIC/WACCN/A
WACC6.7%
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • AAPG has a Current Ratio of 1.54. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
  • AAPG has a worse Current ratio (1.54) than 80.77% of its industry peers.
  • A Quick Ratio of 1.53 indicates that AAPG should not have too much problems paying its short term obligations.
  • AAPG's Quick ratio of 1.53 is on the low side compared to the rest of the industry. AAPG is outperformed by 79.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.53
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • AAPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.96%.
  • AAPG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -56.75%.
  • The Revenue has been growing by 132.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%

3.2 Future

  • The Earnings Per Share is expected to decrease by -39.12% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 22.45% on average over the next years. This is a very strong growth
EPS Next Y-185.96%
EPS Next 2Y104%
EPS Next 3Y9.42%
EPS Next 5Y-39.12%
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.64%
Revenue Next 5Y22.45%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 0 5 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AAPG. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 17.48, which indicates a rather expensive current valuation of AAPG.
  • Based on the Price/Forward Earnings ratio, AAPG is valued cheaply inside the industry as 93.65% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of AAPG to the average of the S&P500 Index (28.11), we can say AAPG is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 17.48
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104%
EPS Next 3Y9.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AAPG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (3/3/2026, 2:06:38 PM)

22.14

-1.52 (-6.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)N/A
Inst Owners11.12%
Inst Owner Change-30.19%
Ins Owners12.72%
Ins Owner ChangeN/A
Market Cap2.06B
Revenue(TTM)390.60M
Net Income(TTM)-1.16B
Analysts86.15
Price Target32.13 (45.12%)
Short Float %0%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.69%
PT rev (3m)-19.13%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.48
P/S 36.27
P/FCF N/A
P/OCF N/A
P/B 21.27
P/tB 24.84
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)1.27
Fwd EY5.72%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.61
BVpS1.04
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.05%
ROE -174.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.87%
FCFM N/A
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score2
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 1.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.84%
Cap/Sales 7.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.53
Altman-Z -0.14
F-Score2
WACC6.7%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
EPS Next Y-185.96%
EPS Next 2Y104%
EPS Next 3Y9.42%
EPS Next 5Y-39.12%
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.64%
Revenue Next 5Y22.45%
EBIT growth 1Y-249.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-258.42%
EBIT Next 3Y-28.37%
EBIT Next 5YN/A
FCF growth 1Y73.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.48%
OCF growth 3YN/A
OCF growth 5YN/A

ASCENTAGE PHARMA GR-ADR / AAPG FAQ

What is the fundamental rating for AAPG stock?

ChartMill assigns a fundamental rating of 2 / 10 to AAPG.


What is the valuation status of ASCENTAGE PHARMA GR-ADR (AAPG) stock?

ChartMill assigns a valuation rating of 1 / 10 to ASCENTAGE PHARMA GR-ADR (AAPG). This can be considered as Overvalued.


Can you provide the profitability details for ASCENTAGE PHARMA GR-ADR?

ASCENTAGE PHARMA GR-ADR (AAPG) has a profitability rating of 2 / 10.


How financially healthy is ASCENTAGE PHARMA GR-ADR?

The financial health rating of ASCENTAGE PHARMA GR-ADR (AAPG) is 2 / 10.